Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › GLAND

GLAND

Gland Pharma Limited
Mid-capPharma ↗

What the six lenses say about GLAND — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2974.3
2026-09-08
VWAP · 1Y anchor
₹2289
+29.9% from VWAP
P/E · TTM
47.7×
TTM EPS ₹62.4
52-week range
100%
position low→high
RSI(14)
70
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How GLAND’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.0
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+29.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+34.8%
Price vs 50-EMA+11.7%
RSI(14)70
RS vs Nifty 500 · 3M+27.9%
RS vs sector · 3M+21.9%
52-week range100%
Volume vs 30d avg0.84×
Volume vs 60d avg0.95×
ATR(14) · volatility101.5
Bollinger width · vol contraction0.067
FundamentalD765›

The actual numbers

Return on equity (ROE)10.7%
Return on capital (ROCE)15.1%
Operating margin23.3%
Net margin16.0%
Revenue growth · YoY+14.5%
EPS growth · YoY+47.1%
Debt / equity0.03×

Full 8-quarter history in the financials table below.

ValuationD414›

The actual numbers

P/E (TTM)47.7×
TTM EPS₹62.4
52-week range100%
CatalystD541›

The actual numbers

Earnings & momentum44
Capital actions6
Governance131

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding51.8%
Delivery · 30d avg51.9%
Up/down-day asymmetry-2.7pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D4 ) ÷ 2 = 7.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 7.0/10
Conviction score95/100›
TechnicalD10›
FundamentalD7›
ValuationD4›
CatalystD5›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.9pp
+4.3pp
+17.5pp
+29.5pp
+81.0pp
+62.4pp
Nifty 500
Broad-market baseline
+1.9pp
+4.3pp
+16.4pp
+27.9pp
+75.2pp
+57.2pp
Sector
Own-sector index
—
—
+13.6pp
+21.9pp
+62.1pp
+36.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

GLAND daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2974.30+41.90

Relative strength

RS vs baseline · rebased to 100

GLAND ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
158.99+2.90

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,4021,4061,3841,4251,5061,4871,6951,743
↳ change QoQ—+0.3%-1.5%+3.0%+5.7%-1.3%+14.0%+2.8%
EBITDA (₹cr)316357418348368314435513
EBITDA margin22.5%25.4%30.2%24.4%24.4%21.1%25.7%29.4%
PAT (₹cr)144164205187215184261367
↳ change QoQ—+13.8%+25.2%-8.6%+15.0%-14.4%+41.8%+40.6%
Net margin10.3%11.6%14.8%13.1%14.3%12.4%15.4%21.1%
EPS (₹)8.739.9312.4211.3213.0811.1515.8722.26
D/E————————
YoY growth · Mar '26Revenue +22.3% YoYPAT +96.3% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Sep '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 23 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 10 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 10 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 9 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 9 Aug '26
    LOWgovernance
    Arrangements for strategic, technical, manufacturing, or marketing tie up
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds GLAND

Mutual funds holding GLAND (10)

FundWeightAUM ₹crGrade
HDFC Mid Cap Gr1.44%1,05,143
Nippon India Small Cap Gr Bns0.58%78,957
Nippon India Small Cap Dir Bns0.58%78,957
Nippon India Small Cap Gr0.58%78,957
Nippon India Multi Cap Gr0.54%55,587
Nippon India Multi Cap Dir Bns0.54%55,587
Nippon India Multi Cap Bns0.54%55,587
Nippon India Growth Md Cp Reg Gr PlGrOpt1.38%50,751
Nippon India Growth Mid Cap Dir Bns1.38%50,751
Nippon India Growth Md Cp Reg Gr Bns1.38%50,751

ETFs holding GLAND (9)

ETFWeightGrade
Nippon India Nifty Pharma ETF2.02%
Zerodha Nifty Smallcap 100 ETF1.70%
Mirae Asset Nifty 500 Healthcare ETF1.43%
Motilal Oswal BSE Healthcare ETF1.23%
DSP Nifty Smallcap 250 ETF0.97%
HDFC Nifty Smallcap 250 ETF0.93%
Motilal Oswal Nifty Smallcap 250 ETF0.93%
Mirae Asset Nifty Smallcap 250 ETF0.93%
Groww Nifty Smallcap 250 ETF0.92%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma